Thromboprophylaxis with rivaroxaban or enoxaparin did not differ for major bleeding in knee arthroplasty

Kamphuisen, Pieter W.
October 2008
ACP Journal Club;10/21/2008, Vol. 149 Issue 4, p5
Academic Journal
The article focuses on efficacy of anticoagulants thromboprophylaxis with rivaroxaban or enoxaparin in preventing bleeding in knee anthroplasty. Hip and knee arthroplasty are associated with a high risk for venous thromboembolism and the use of anticoagulants like warfarin with thromboprophylaxis poses the need for anticoagulant monitoring and subcutaneous administration. It states that neither rivaroxaban nor enoxaparin group differ for major bleeding in knee anthroplasty.


Related Articles

  • ORAL DIRECT THROMBIN INHIBITOR XIMELAGATRAN COMPARED WITH WARFARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE ARTHROPLASTY. Colwell, Jr., Clifford W.; Berkowitz, Scott D.; Lieberman, Jay R.; Comp, Philip C.; Ginsberg, Jeffrey S.; Paiement, Guy; McElhattan, Jennifer; Roth, Anne W.; Francis, Charles W. // Journal of Bone & Joint Surgery, American Volume;Oct2005, Vol. 87-A Issue 10, p2169 

    Background: Warfarin, which requires coagulation monitoring, is associated with relatively high rates of thromboembolism despite providing adequate prophylaxis. This study compared an oral direct thrombin inhibitor, ximelagatran, with warfarin in order to evaluate the safety and efficacy of the...

  • Rivaroxaban cost effective in various settings. Joshi, Nitin // PharmacoEconomics & Outcomes News;11/29/2008, Issue 567, p2 

    Recently completed RECORD trials have shown that rivaroxaban has better efficacy and safety than enoxaparin sodium when used prophylactically for venous thromboembolism (VTE) after major orthopaedic surgeries like total hip replacement (THR) and total knee replacement (TKR). Using data from the...

  • Rivaroxaban rates in Russia for preventing VTE after surgery.  // PharmacoEconomics & Outcomes News;6/11/2011, Issue 630, p4 

    The article deals with two studies which examine the effectiveness of rivaroxaban compared with dabigatran and enoxaparin for the prevention of venous thromboembolism after total hip and total knee replacement, presented at the 16th Annual International Meeting of the International Society for...

  • Discontinuation of warfarin is unnecessary in total knee arthroplasty.  // Advances in Orthopaedics;Sep2010, Vol. 2 Issue 3, p125 

    In this study, patients with osteoarthritis requiring arthroplasty who were on a regimen of warfarin preoperatively had their warfarin either continued or discontinued and replaced with low-molecular-weight heparin. Patients who were continued on warfarin had fewer complications and were less...

  • Complications After Revision Total Knee Arthroplasty. Saleh, Khaled J.; Hoeffel, Daniel P.; Kassim, Rida A.; Burstein, Gideon // Journal of Bone & Joint Surgery, American Volume;Jan2003 Supplement, Vol. 85-A, p71 

    Focuses on the available knowledge regarding selected complications of revision total knee arthroplasty. Description of the most common neurovascular complications that involves the peroneal nerve; Mechanisms of vascular injury that have been proposed by specialists; Prevalence and treatment of...

  • Ximelagtran reduced venous thromboembolism more than warfarin after total knee replacement. Francis, C. W.; Beerkowitz, S. D.; Comp, P. C. // Evidence Based Medicine;Jul/Aug2004, Vol. 9 Issue 4, p106 

    The article presents results of comparison of ximelagtran with warfarin for the prevention of venous thromboembolism after total knee replacement. Fewer patients who received ximelagatran 36 mg, had an occurrence of the composite primary endpoint than did patients who received warfarin. The...

  • Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty. Lassen, Michael R.; Ageno, Walter; Borris, Lars C.; Lieberman, Jay R.; Rosencher, Nadia; Bandel, Tiemo J.; Misselwitz, Frank; Turpie, Alexander G.G. // New England Journal of Medicine;6/26/2008, Vol. 358 Issue 26, p2776 

    Background: We investigated the efficacy of rivaroxaban, an orally active direct factor Xa inhibitor, in preventing venous thrombosis after total knee arthroplasty. Methods: In this randomized, double-blind trial, 2531 patients who were to undergo total knee arthroplasty received either oral...

  • Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.  // Advances in Orthopaedics;Sep2010, Vol. 2 Issue 3, p129 

    In this study, the authors analyzed the cost-effectiveness of dabigatran etexilate in patients aged >75 years or with moderate renal insufficiency undergoing major arthroplasty, finding that dabigatran was at least equivalent to enoxaparin in these patients.

  • Rivaroxaban vs Dabigatran for Thromboprophylaxis After Joint-replacement Surgery: Exploratory Indirect Comparison Based on Metaanalysis of Pivotal Clinical Trials. Trkulja, Vladimir; Kolundžić, Robert // Croatian Medical Journal;Apr2010, Vol. 51 Issue 2, p113 

    Aim To indirectly compare rivaroxaban and dabigatran for prevention of venous thromboembolism (VTE) after total hip or knee arthroplasty (THA, TKA) based on their pivotal efficacy/safety trials embracing a total of 20 618 patients. Methods Pooled risk differences (RD) for rivaroxaban vs...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics